BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment
New Concussion-Specific FDA Labeling Adds to Existing BrainScope Claims Complements Multi-Modal Technology Platform and Extensive Intellectual Property Portfolio To Address New Brain and Behavioral Health Conditions
BETHESDA, MD. January 2, 2019– BrainScope®, a medical neuro-technology company focused on..